MA40364A - Polythérapie pour le traitement du cancer - Google Patents

Polythérapie pour le traitement du cancer

Info

Publication number
MA40364A
MA40364A MA040364A MA40364A MA40364A MA 40364 A MA40364 A MA 40364A MA 040364 A MA040364 A MA 040364A MA 40364 A MA40364 A MA 40364A MA 40364 A MA40364 A MA 40364A
Authority
MA
Morocco
Prior art keywords
cancer
treatment
combination therapy
combination
staggered
Prior art date
Application number
MA040364A
Other languages
English (en)
Inventor
Austin Gurney
Wan-Ching Yen
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MA40364A publication Critical patent/MA40364A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés comprenant la polythérapie pour le traitement du cancer. Elle concerne également des inhibiteurs de la voie wnt en combinaison avec des inhibiteurs mitotiques administrés de manière échelonnée ou selon un dosage séquentiel pour le traitement du cancer et d'autres maladies.
MA040364A 2014-08-27 2015-08-27 Polythérapie pour le traitement du cancer MA40364A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462042710P 2014-08-27 2014-08-27
US201462086376P 2014-12-02 2014-12-02
US201562134661P 2015-03-18 2015-03-18

Publications (1)

Publication Number Publication Date
MA40364A true MA40364A (fr) 2016-03-03

Family

ID=55400550

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040364A MA40364A (fr) 2014-08-27 2015-08-27 Polythérapie pour le traitement du cancer

Country Status (9)

Country Link
US (1) US20170247465A1 (fr)
EP (1) EP3185884A4 (fr)
JP (1) JP2017526676A (fr)
CN (1) CN106714822A (fr)
AU (1) AU2015308854A1 (fr)
CA (1) CA2959529A1 (fr)
MA (1) MA40364A (fr)
MX (1) MX2017002364A (fr)
WO (1) WO2016033284A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
EP4183806A3 (fr) 2014-11-12 2023-08-02 Seagen Inc. Composés interagissant avec le glycane et procédés d'utilisation
WO2017040666A2 (fr) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Polythérapie pour le traitement d'une maladie
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
WO2018094143A1 (fr) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Composés interagissant avec le glycane et méthodes d'utilisation
WO2018160909A1 (fr) * 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Composés interagissant avec le glycane et méthodes d'utilisation
WO2019124603A1 (fr) * 2017-12-22 2019-06-27 경상대학교병원 Composition destinée à prévenir ou à traiter une chéloïde contenant iwr-1 à titre de principe actif
JP7369968B2 (ja) * 2017-12-27 2023-10-27 公益財団法人がん研究会 抗がん剤
EP3784240B1 (fr) * 2018-04-24 2023-09-20 Universidade do Minho Wnt6 comme biomarqueur oncogènique du glioblastome, et utilisations d'inhibiteurs associés pour traiter le glioblastome surexprimant wnt6
CN113648425B (zh) * 2021-08-18 2022-05-03 中国人民解放军军事科学院军事医学研究院 Plk1抑制剂和csnk1d/e抑制剂对肿瘤细胞具有协同抑制作用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663536T3 (es) * 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
CN102971337B (zh) * 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
HK1212216A1 (en) * 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) * 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング

Also Published As

Publication number Publication date
WO2016033284A1 (fr) 2016-03-03
MX2017002364A (es) 2017-05-17
EP3185884A4 (fr) 2018-04-11
US20170247465A1 (en) 2017-08-31
WO2016033284A4 (fr) 2016-04-28
AU2015308854A1 (en) 2017-03-02
EP3185884A1 (fr) 2017-07-05
CA2959529A1 (fr) 2016-03-03
CN106714822A (zh) 2017-05-24
JP2017526676A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
MA40364A (fr) Polythérapie pour le traitement du cancer
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
PH12017500601A1 (en) Anti-tnf compounds
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
IL256684B (en) Medicinal compounds and preparations for the treatment of social disorders and substance use disorders
PL3242947T3 (pl) Terapia genowa i elektroporacja do leczenia zmian złośliwych
MX2017002489A (es) Agentes terapeuticos humanos.
IL277238A (en) Modified oligonucleotides for use in the treatment of tauopathy
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
SMT202300244T1 (it) Inibitori di pi3k p-delta 110 per uso nell’erogazione di virus nel trattamento di cancro
EP3156054A4 (fr) Médicament pour la prévention et/ou le traitement de maladies induites par le stress
IL248328A0 (en) Bracelets for the administration of drugs for the treatment of resistant cancer and for the use of combined therapy
IL245861A0 (en) Use of substances to treat drug-resistant tumors
MA40574A (fr) Traitement de maladies fibrotiques
PH12020500472A1 (en) Autotaxin inhibitor compounds
HK1242990A1 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer